Product Images Clopidogrel

This is a description of a medication called "Clopidogrel" in tablet form. The tablets are manufactured by Accord Healthcare, Inc. and are stamped with the National Drug Code (NDC) number 16729-219-45. The medication comes in a bottle with a specific manufacturing lot number and expiration date. The tablets are USP graded and the bottle also indicates that the medication was made in India.*

Each package contains 100 tablets of Clopidogrel USP, used to prevent blood clots after a recent heart attack or stroke. It is important to provide each patient with the enclosed Medication Guide. Store the tablets between 15-30°C. This medicine requires a pharmacist prescription to be dispensed.*

This is a description of a medication containing 97,875mg of clopidogrel bisulfate, equivalent to 75mg of clopidogrel base per film-coated tablet. The tablet is stored within a temperature range of 15 to 30°C and the usual dosage is available in the package insert. Additionally, a medication guide is available on the website provided. The medication is manufactured by Intas Pharmaceuticals Limited in Ahmedabad, India for Accord Healthcare, Inc. in Durham, NC, USA.*

This is a product label for Clopidogrel tablets in 75mg strength. The tablets are manufactured by Intas Pharmaceuticals Limited in India and are distributed by Accord Healthcare, Inc. in Durham, NC. The label includes the NDC numbers, lot numbers, and manufacturing information for the product.*

This is a description of Clopidogrel Tablets USP manufactured by Accord Healthcare. The package comes with 100 unit-dose tablets (10 x 10) each containing 97.875 mg of clopidogrel bisulfate USP that is equivalent to 75 mg of clopidogrel base. The medicine should be stored between the temperature ranges of 15°C to 30°C (59 to 86°F). The package also contains a medication guide that is available on https:/www.accordhealthcare.us/ ‘medication-guides. The text also mentions a "varnish free area" for overcoding, but it is unclear what that refers to.*

The text provides a chart showing the cumulative event rate of fatal or non-fatal vascular events when using Aspirin and Clopidogrel Bisulfate over the course of 36 months of follow-up. The chart indicates that at the 16 month mark, both drugs had a cumulative event rate of 12%. At the end of the follow-up period, the chart shows that Clopidogrel Bisulfate had a lower event rate compared to Aspirin, with a statistically significant difference (P=0.045). The chart also includes time points at 6, 12, 18, 24, 30, and 36 months.*

This is a chart displaying the cumulative event rate percentage of cardiovascular death, myocardial infarction, and stroke over a period of 12 months follow-up. The placebo (+ aspirin) and clopidogrel bisulfate (+ aspirin) treatments are compared. The P value is shown to be 0.00009. Other standard therapies were also used in the study.*

Not available*

This appears to be a report of a clinical trial comparing the effects of a placebo and a drug called clopidogrel on mortality. The text shows the number of deaths before the first discharge, with the placebo group having 8.1% deaths and the clopidogrel group having 7.5% deaths. There was a 7% proportional risk reduction in mortality with clopidogrel compared to placebo, with a p-value of 0.03. The report includes data up to 28 days since randomization.*

The text refers to the result of a research study with the goal of showing the effectiveness of Clopidogrel in reducing the risk of death, re-infarction or stroke before first discharge in patients with a recent history of heart attack. The study involved two groups, one that received placebo and one that received Clopidogrel. After a randomization process that lasted up to 28 days, the group that received Clopidogrel showed a 9% proportional risk reduction compared to the group that received placebo, which was statistically significant (p = 0.002).*